Arvinas, Inc

(NASDAQ:ARVN)

$25.95

Created with Raphaël 2.1.2295-100100
STRONG BUY

Latest On Arvinas, Inc (ARVN):

About Arvinas, Inc (ARVN):

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

See Advanced Chart

General

  • Name Arvinas, Inc
  • Symbol ARVN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 179
  • Fiscal Year EndDecember
  • IPO Date2018-09-27
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.arvinas.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 131.11
  • Price/Book (Most Recent Quarter) 5.5
  • Enterprise Value Revenue 130.68
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.37
  • Next Year EPS Estimate -$3.96
  • Next Quarter EPS Estimate -$0.73
  • Operating Margin -573%
  • Return on Assets -15%
  • Return on Equity -27%
  • Revenue 21.8 million
  • Earnings Per Share -$7.16
  • Revenue Per Share $0.55
  • Gross Profit 21.8 million
  • Quarterly Earnings Growth -54.7%
View More

Highlights

  • Market Capitalization 3.26 billion
  • EBITDA -64270736
  • PE Ratio -5.55
  • Analyst Target Price $102.5
  • Book Value Per Share $13.26
View More

Share Statistics

  • Shares Outstanding 48.46 million
  • Shares Float 41.19 million
  • % Held by Insiders 1204%
  • % Held by Institutions 76.78%
  • Shares Short 1.78 million
  • Shares Short Prior Month 1.64 million
  • Short Ratio 3.96
  • Short % of Float 4%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 2.18
  • 52 Week High $92.77
  • 52 Week Low $19.68
  • 50 Day Moving Average 76.84
  • 200 Day Moving Average 49.59
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arvinas, Inc (ARVN) Dividend Calendar:

-$0.28-$0.28-$0.46-$0.46-$0.64-$0.64-$0.81-$0.81-$0.99-$0.99EPSQ3/2018Q3/2018Q4/2018Q4/2018Q1/2019Q1/2019Q2/2019Q2/2019Q3/2019Q3/2019Q4/2019Q4/2019Q1/2020Q1/2020Q2/2020Q2/2020Q3/2020Q3/2020Q4/2020Q4/2020Date
EPS
EPS Estimate

Arvinas, Inc (ARVN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Arvinas, Inc (ARVN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arvinas, Inc (ARVN) Chart:

Arvinas, Inc (ARVN) News:

Below you will find a list of latest news for Arvinas, Inc (ARVN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arvinas, Inc (ARVN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Latest ARVN Trades:

Arvinas, Inc (ARVN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Arvinas, Inc (ARVN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arvinas, Inc (ARVN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1204%
Institutional Ownership: 7678%